Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher White

General Practice Memphis, TN Medical Doctor

NPI 1316987639 CMS profile 286440

2911 Brunswick Road, Memphis, TN 38133

Open in the dashboard

General payments

$4,136

205 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christopher White of Memphis, TN is reported in the CMS Open Payments database as having received $4,136 across 205 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,308 51
2024 General $523 26
2023 General $1,028 51
2022 General $458 31
2021 General $352 21
2020 General $216 14
2019 General $250 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher White
  • General Practice median
  • Middle half of General Practice
  • National median

In program year 2025, general payments to Christopher White were reported at $1,308. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.

Show as a table
Year Christopher White General Practice median Middle half National median
2019 $250 $107 $37–$285 $163
2020 $216 $75 $25–$213 $114
2021 $352 $93 $30–$272 $132
2022 $458 $103 $36–$279 $149
2023 $1,028 $106 $34–$276 $160
2024 $523 $114 $39–$290 $164
2025 $1,308 $106 $35–$292 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alkermes, Inc. $553 24 payments
  2. Janssen Pharmaceuticals, Inc $504 29 payments
  3. AbbVie, Inc. $389 26 payments
  4. LivaNova USA, Inc. $347 4 payments
  5. E.R. Squibb & Sons, L.L.C. $342 17 payments
  6. Teva Pharmaceuticals USA, Inc. $296 7 payments
  7. Indivior Inc. $296 21 payments
  8. Allergan Inc. $246 10 payments
  9. Otsuka America Pharmaceutical, Inc. $231 15 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $153 8 payments
  11. Other $779 44 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,834 200 payments
  2. Education $302 5 payments
Products named General payments · program years 2019–2025
  1. LYBALVI $471 19 payments
  2. ARISTADA Cns $399 22 payments
  3. ARISTADA Cns $399 22 payments
  4. INVEGA SUSTENNA $373 21 payments
  5. VRAYLAR Neuroscience $358 25 payments
  6. VNS THERAPY SYMMETRY MODEL 8103 GENERATOR $347 4 payments
  7. COBENFY $342 17 payments
  8. ARISTADA Cns $311 17 payments
  9. ARISTADA Cns $311 17 payments
  10. VRAYLAR Neuroscience $277 11 payments
  11. Other $2,489 129 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 42 drugs

Part D claims

1,772

Median for Psychiatry: 574

Drug cost

$57,525

Median for Psychiatry: $27,624

Branded share of claims

25.7%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Divalproex Sodium Er Divalproex Sodium Brand 103 $8,417
Vyvanse Lisdexamfetamine Dimesylate Brand 18 $6,467
Quetiapine Fumarate Generic 96 $4,077
Clozapine Generic 40 $3,907
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 27 $3,824
Aripiprazole Generic 32 $2,980
Loxapine Loxapine Succinate Brand 15 $2,958
Oxcarbazepine Generic 52 $2,863
Bupropion Xl Bupropion Hcl Brand 89 $2,829
Haloperidol Generic 47 $2,242

The 10 drugs with the highest cost, of 42 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 3 billing codes

Paid by Medicare

$43,584

Medicare's payments for the services billed

Medicare patients

46

Average age 60

Services billed

673

20 women, 26 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 65%
Arthritis 52%
Diabetes 33%
Ischemic heart disease 30%
Alzheimer's or dementia 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INVEGA SUSTENNA
  • Janssen Pharmaceuticals, Inc $92
$92 — —
ARISTADA
  • Alkermes, Inc. $62
$62 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $56
$56 — —
TRINTELLIX
  • Takeda Pharmaceuticals U.S.A., Inc. $45
$45 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $38
$38 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

205 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record